Should You Buy Coherus Oncology, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Coherus Oncology, Inc. (CHRS) occupies a solid middle-ground position with a Quality of Company score of 6.1/10. At the current market price of $1.47, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 4 of 10 CirclFi valuation models project upside for Coherus Oncology, Inc. (CHRS) at $1.47 — the model consensus leans bearish, with a Quality Score of 6.1/10 and Value-Trap risk of 53/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $7.18 (+388.7% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with an average implied return of +46.9% across 4 bullish models from the current price of $1.47.
- According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model targets a fair value of $7.18 (+388.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
The Bear Case
Target: $0.47 (-67.7%)
- According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality.
- According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.47 (-67.7%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +456.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
The Bottom Line
Caution dominates our read on Coherus Oncology, Inc. at $1.47. 6 of 10 models see limited upside or outright downside, with the composite fair value at $2.16 (+46.9%). Quality at 6.1/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Coherus Oncology, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy CHRS stock right now?
Based on CirclFi's multi-model analysis, 4 of 10 models see upside for CHRS at $1.47. The models are divided, which means the investment case depends heavily on your assumptions about Coherus Oncology, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Coherus Oncology, Inc.?
Key risks include: an elevated Value Trap score of 53/100, suggesting apparent undervaluation may mask deteriorating fundamentals; wide model disagreement (1415% spread), signaling high uncertainty; general market and sector-specific risks affecting Biological Products, (No Diagnostic Substances) companies. Always diversify and consult a financial advisor.
How does CHRS compare to its competitors?
Among Biological Products, (No Diagnostic Substances) peers, CHRS holds a Quality Score of 6.1/10. Comparable companies include EXEL (QOC 10.0), HALO (QOC 10.0), NBIX (QOC 10.0). The relative ranking helps investors identify whether CHRS offers better fundamental quality than alternatives in the same sector.
Is CHRS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CHRS's Quality Score of 6.1/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy CHRS at?
CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $0.47 to $7.18. At $1.47, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CHRS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad